The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy–from basic research to clinical application.
Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for JITC, an outlet devoted to and created by today's leaders in the field.
Read the Journal for ImmunoTherapy of Cancer (JITC)
The Journal for ImmunoTherapy of Cancer (JITC) received its first impact factor of 8.374 on June 26, 2018. JITC’s impact factor ranks in the top 8 percent of all journals published in the categories of oncology and immunology.
Published in the annual Journal Citation Reports (JCR), the impact factor is a calculation determined on the number of 2017 citations accumulated for JITC manuscripts published in 2015 and 2016. Other journal metrics for JITC can be found on the journal website.
JITC seeks submissions to its Basic Tumor Immunology section
Edited by Cornelis J.M. Melief, MD, PhD, the Basic Tumor Immunology section publishes on topics that include Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, other combination treatments with the anti-tumor immune response, and oncolytic viruses.
Submit your manuscript today to the open access journal.
As a way to thank the dedicated society members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, one article per SITC member is eligible for waived article processing charges through 2018. To take advantage of this $2,400 value member benefit, contact SITC at +1 414-271-2456 or JITCEditor@sitcancer.org for your member code prior to submission.
Basic Tumor Immunology
Clinical Trials Monitor
Clinical/Translational Cancer Immunotherapy
Guidelines and Consensus Statements
Indicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm and represents a weighted count of the amount of attention picked up for a research output. Learn more here.
Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy – characterized by some benefit but only rare durable responses – was the only treatment option for patients with NSCLC whose tumors lacked targetable mutations. By contrast, immune checkpoint inhibitors have demonstrated distinctly durable responses and represent the advent of a new treatment approach for patients with NSCLC. Three immune checkpoint inhibitors, pembrolizumab, nivolumab and atezolizumab, are now approved for use in first- and/or second-line settings for selected patients with advanced NSCLC, with promising benefit also seen in patients with stage III NSCLC...
Recent advances in our understanding of the dynamics of cellular cross-talk have highlighted the significance of host-versus-tumor effect that can be harnessed with immune therapies. Tumors exploit immune checkpoints to evade adaptive immune responses. Cancer immunotherapy has witnessed a revolution in the past decade with the development of immune checkpoint inhibitors (ICIs), monoclonal antibodies against cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) or their ligands, such as PD1 ligand 1 (PD-L1). ICIs have been reported to have activity against a broad range of tumor types, in both solid organ and hematologic malignancy contexts...
Metformin is one of the biguanides commonly used in patients with type II Diabetes Mellitus. Apart from its hypoglycemic properties, metformin also inhibits the cell cycle by restricting protein synthesis and cell proliferation via regulating the LKB1/AMPL pathway. Furthermore, it also enhances the PD-1 blockade through a reduction of tumor hypoxia. Metformin has shown a significant favorable impact on treatment-related outcomes in solid tumors, but these outcomes have not been replicated in the limited clinical studies done on malignant melanoma. Moreover, none of these studies have reported on the efficacy of the combined use of metformin and immune checkpoint inhibitors (ICIs).
Dear Sir /Madam Thank you for your invitation. Regards, Saroj Kumar Pathway India ------Original Message------ 2019 , 04-05 March
Global Conference on Cancer & Oncology Research
Global Conference on Cancer ...
2019 , 04-05 March
Global Conference on Cancer & Oncology Research
Global Conference on Cancer & Oncology Research to be held on March 04-05, 2019 at Dubai, UAE hosted by Ology Mavens.
Call For Papers
We invite you ...
Dear colleagues, Dear participants,
I would like to invite you to attend and participate actively in our
ISOBM (International Society of Oncology and BioMarkers) 2018 CONGRESS, to be held in Hamburg, Germany, on November 24 - 27, 2018. ...
------------------------------ Vennela Desouza Conference Manager Ology Mavens ------------------------------
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com